000262282 001__ 262282
000262282 005__ 20190619220113.0
000262282 022__ $$a0949-8257
000262282 022__ $$a1432-1327
000262282 02470 $$a000448583900020$$2isi
000262282 0247_ $$a10.1007/s00775-018-1597-x$$2doi
000262282 037__ $$aARTICLE
000262282 245__ $$aUnderstanding the interactions of diruthenium anticancer agents with amino acids
000262282 260__ $$c2018$$aNew York$$bSPRINGER
000262282 269__ $$a2018-10-01
000262282 336__ $$aJournal Articles
000262282 520__ $$aThe dinuclear anticancer agents 1,n-bis{chlorido[3-(oxo-kappa O)-2-methyl-4-(1H)-pyridinonato-kappa O4](eta(6)-p-cymene)-ruthenium(II)}alkane (PyRu2n) exhibit high antiproliferative activity in human cancer cell. Reactivity studies with DNA and protein revealed uncommon protein-DNA and DNA-DNA crosslinking ability. We report here studies on the reactions of the diruthenium organometallics PyRu26 and PyRu28 in comparison with a mononuclear analogue PyRu3 with amino acids using mass spectrometry and NMR spectroscopy. The compounds behave very similarly, independent of the spacer length between the metal center and of the nuclearity of the complexes. Incubation with L-cysteine (Cys) results in fast release of the pyridone ligand, with the Ru complexes able to form Cys adducts. In contrast, L-methionine forms, initially, adducts with the metal centers, but over time, the adducts decompose. Similar behavior was observed for the reaction with L-histidine with [Ru(eta(6)-p-cymene)(L-histidine)] species detected.
000262282 650__ $$aBiochemistry & Molecular Biology
000262282 650__ $$aChemistry, Inorganic & Nuclear
000262282 650__ $$aBiochemistry & Molecular Biology
000262282 650__ $$aChemistry
000262282 6531_ $$aamino acid interaction
000262282 6531_ $$abioorganometallics
000262282 6531_ $$adinuclear compounds
000262282 6531_ $$amass spectrometry
000262282 6531_ $$anmr spectroscopy
000262282 6531_ $$aruthenium(arene) complexes
000262282 6531_ $$aruthenium(ii)-arene complexes
000262282 6531_ $$aruthenium complexes
000262282 6531_ $$aantitumor-activity
000262282 6531_ $$ain-vitro
000262282 6531_ $$aphase-i
000262282 6531_ $$acytotoxicity
000262282 6531_ $$adrugs
000262282 6531_ $$adna
000262282 6531_ $$achemotherapy
000262282 6531_ $$ametallodrugs
000262282 700__ $$g182952$$0242063$$aNazarov, Alexey A.
000262282 700__ $$aMendoza-Ferri, Maria-Grazia
000262282 700__ $$aHanif, Muhammad
000262282 700__ $$aKeppler, Bernhard K.
000262282 700__ $$g149418$$0240015$$aDyson, Paul J.
000262282 700__ $$aHartinger, Christian G.$$0241992$$g175201
000262282 773__ $$k7$$j23$$q1159-1164$$tJournal Of Biological Inorganic Chemistry
000262282 909C0 $$pLCOM$$0252010$$xU9
000262282 909CO $$particle$$ooai:infoscience.epfl.ch:262282$$pSB
000262282 973__ $$aEPFL$$sPUBLISHED$$rREVIEWED
000262282 980__ $$aARTICLE
000262282 980__ $$aWoS
000262282 981__ $$aoverwrite
000262282 999C0 $$xU10109$$pLCS$$zBorel, Alain$$mkay.severin@epfl.ch$$0252071